Tian Ge1, Mert R Sabuncu1, Jordan W Smoller1, Reisa A Sperling1, Elizabeth C Mormino2. 1. From the Psychiatric and Neurodevelopmental Genetics Unit (T.G., J.W.S.), Center for Genomic Medicine, Massachusetts General Hospital; Departments of Psychiatry (T.G., J.W.S.) and Neurology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (T.G., M.R.S.), Massachusetts General Hospital, Harvard Medical School, Charleston; School of Electrical and Computer Engineering and Nancy E. and Peter C. Meinig School of Biomedical Engineering (M.R.S.), Cornell University, Ithaca, NY; Center for Alzheimer Research and Treatment (R.A.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Department of Neurology and Neurological Sciences (E.C.M.), Stanford University School of Medicine, Palo Alto, CA. 2. From the Psychiatric and Neurodevelopmental Genetics Unit (T.G., J.W.S.), Center for Genomic Medicine, Massachusetts General Hospital; Departments of Psychiatry (T.G., J.W.S.) and Neurology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (T.G., M.R.S.), Massachusetts General Hospital, Harvard Medical School, Charleston; School of Electrical and Computer Engineering and Nancy E. and Peter C. Meinig School of Biomedical Engineering (M.R.S.), Cornell University, Ithaca, NY; Center for Alzheimer Research and Treatment (R.A.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Department of Neurology and Neurological Sciences (E.C.M.), Stanford University School of Medicine, Palo Alto, CA. bmormino@stanford.edu.
Abstract
OBJECTIVE: To investigate the effects of genetic risk of Alzheimer disease (AD) dementia in the context of β-amyloid (Aβ) accumulation. METHODS: We analyzed data from 702 participants (221 clinically normal, 367 with mild cognitive impairment, and 114 with AD dementia) with genetic data and florbetapir PET available. A subset of 669 participants additionally had longitudinal MRI scans to assess hippocampal volume. Polygenic risk scores (PRSs) were estimated with summary statistics from previous large-scale genome-wide association studies of AD dementia. We examined relationships between APOE ε4 status and PRS with longitudinal Aβ and cognitive and hippocampal volume measurements. RESULTS: APOE ε4 was strongly related to baseline Aβ, whereas only weak associations between PRS and baseline Aβ were present. APOE ε4 was additionally related to greater memory decline and hippocampal atrophy in Aβ+ participants. When APOE ε4 was controlled for, PRS was related to cognitive decline in Aβ+ participants. Finally, PRSs were associated with hippocampal atrophy in Aβ- participants and weakly associated with baseline hippocampal volume in Aβ+ participants. CONCLUSIONS: Genetic risk factors of AD dementia demonstrate effects related to Aβ, as well as synergistic interactions with Aβ. The specific effect of faster cognitive decline in Aβ+ individuals with higher genetic risk may explain the large degree of heterogeneity in cognitive trajectories among Aβ+ individuals. Consideration of genetic variants in conjunction with baseline Aβ may improve enrichment strategies for clinical trials targeting Aβ+ individuals most at risk for imminent cognitive decline.
OBJECTIVE: To investigate the effects of genetic risk of Alzheimer disease (AD) dementia in the context of β-amyloid (Aβ) accumulation. METHODS: We analyzed data from 702 participants (221 clinically normal, 367 with mild cognitive impairment, and 114 with AD dementia) with genetic data and florbetapir PET available. A subset of 669 participants additionally had longitudinal MRI scans to assess hippocampal volume. Polygenic risk scores (PRSs) were estimated with summary statistics from previous large-scale genome-wide association studies of AD dementia. We examined relationships between APOE ε4 status and PRS with longitudinal Aβ and cognitive and hippocampal volume measurements. RESULTS: APOE ε4 was strongly related to baseline Aβ, whereas only weak associations between PRS and baseline Aβ were present. APOE ε4 was additionally related to greater memory decline and hippocampal atrophy in Aβ+ participants. When APOE ε4 was controlled for, PRS was related to cognitive decline in Aβ+ participants. Finally, PRSs were associated with hippocampal atrophy in Aβ- participants and weakly associated with baseline hippocampal volume in Aβ+ participants. CONCLUSIONS: Genetic risk factors of AD dementia demonstrate effects related to Aβ, as well as synergistic interactions with Aβ. The specific effect of faster cognitive decline in Aβ+ individuals with higher genetic risk may explain the large degree of heterogeneity in cognitive trajectories among Aβ+ individuals. Consideration of genetic variants in conjunction with baseline Aβ may improve enrichment strategies for clinical trials targeting Aβ+ individuals most at risk for imminent cognitive decline.
Authors: Mert R Sabuncu; Randy L Buckner; Jordan W Smoller; Phil Hyoun Lee; Bruce Fischl; Reisa A Sperling Journal: Cereb Cortex Date: 2011-12-13 Impact factor: 5.357
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust Journal: Brain Date: 2008-11-28 Impact factor: 13.501
Authors: Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2010-08-26 Impact factor: 13.491
Authors: Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302
Authors: Valentina Escott-Price; Rebecca Sims; Christian Bannister; Denise Harold; Maria Vronskaya; Elisa Majounie; Nandini Badarinarayan; Kevin Morgan; Peter Passmore; Clive Holmes; John Powell; Carol Brayne; Michael Gill; Simon Mead; Alison Goate; Carlos Cruchaga; Jean-Charles Lambert; Cornelia van Duijn; Wolfgang Maier; Alfredo Ramirez; Peter Holmans; Lesley Jones; John Hardy; Sudha Seshadri; Gerard D Schellenberg; Philippe Amouyel; Julie Williams Journal: Brain Date: 2015-10-21 Impact factor: 13.501
Authors: Gary W Beecham; Kara Hamilton; Adam C Naj; Eden R Martin; Matt Huentelman; Amanda J Myers; Jason J Corneveaux; John Hardy; Jean-Paul Vonsattel; Steven G Younkin; David A Bennett; Philip L De Jager; Eric B Larson; Paul K Crane; M Ilyas Kamboh; Julia K Kofler; Deborah C Mash; Linda Duque; John R Gilbert; Harry Gwirtsman; Joseph D Buxbaum; Patricia Kramer; Dennis W Dickson; Lindsay A Farrer; Matthew P Frosch; Bernardino Ghetti; Jonathan L Haines; Bradley T Hyman; Walter A Kukull; Richard P Mayeux; Margaret A Pericak-Vance; Julie A Schneider; John Q Trojanowski; Eric M Reiman; Gerard D Schellenberg; Thomas J Montine Journal: PLoS Genet Date: 2014-09-04 Impact factor: 5.917
Authors: Elizabeth C Mormino; Reisa A Sperling; Avram J Holmes; Randy L Buckner; Philip L De Jager; Jordan W Smoller; Mert R Sabuncu Journal: Neurology Date: 2016-07-06 Impact factor: 9.910
Authors: Vijay K Ramanan; Michael G Heckman; Scott A Przybelski; Timothy G Lesnick; Val J Lowe; Jonathan Graff-Radford; M Mielke; Clifford R Jack; David S Knopman; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Jonathan Graff-Radford; Nilufer Ertekin-Taner; Mary M Machulda; Joseph R Duffy; Christopher G Schwarz; Matthew L Senjem; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Neurobiol Aging Date: 2021-08-25 Impact factor: 5.133
Authors: Kevin Duff; Kayla R Suhrie; Dustin B Hammers; Ava M Dixon; Jace B King; Vincent Koppelmans; John M Hoffman Journal: Clin Neuropsychol Date: 2021-10-29 Impact factor: 4.373
Authors: Chin Hong Tan; Luke W Bonham; Chun Chieh Fan; Elizabeth C Mormino; Leo P Sugrue; Iris J Broce; Christopher P Hess; Jennifer S Yokoyama; Gil D Rabinovici; Bruce L Miller; Kristine Yaffe; Gerard D Schellenberg; Karolina Kauppi; Dominic Holland; Linda K McEvoy; Walter A Kukull; Duygu Tosun; Michael W Weiner; Reisa A Sperling; David A Bennett; Bradley T Hyman; Ole A Andreassen; Anders M Dale; Rahul S Desikan Journal: Brain Date: 2019-02-01 Impact factor: 13.501
Authors: Chun Chieh Fan; Sarah J Banks; Wesley K Thompson; Chi-Hua Chen; Linda K McEvoy; Chin Hong Tan; Walter Kukull; David A Bennett; Lindsay A Farrer; Richard Mayeux; Gerard D Schellenberg; Ole A Andreassen; Rahul Desikan; Anders M Dale Journal: Brain Date: 2020-07-01 Impact factor: 13.501
Authors: Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski Journal: Alzheimers Dement Date: 2021-09-28 Impact factor: 16.655
Authors: Kacie D Deters; Valerio Napolioni; Reisa A Sperling; Michael D Greicius; Richard Mayeux; Timothy Hohman; Elizabeth C Mormino Journal: Neurology Date: 2021-02-10 Impact factor: 9.910